Splenic tuberculosis during psoriasis treatment with infliximab;Tuberculose esplênica durante tratamento de psoríase com infliximabe

Anais Brasileiros de Dermatologia

Volumn 84, Issue 4, 2009, Pages 420-424

  Fortaleza, Gleyce Tavares De Melo ^a   Brito, Maria De Fátima De Medeiros ^a   Dos Santos, Josemir Belo ^a   Figueiredo, Ana Roberta ^a   Gomes, Perla ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Biological therapy; Psoriasis; Tuberculosis

Indexed keywords

INFLIXIMAB; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; HISTOPATHOLOGY; HOST RESISTANCE; HUMAN; LABORATORY TEST; MYCOBACTERIUM TUBERCULOSIS; PSORIASIS; THORAX RADIOGRAPHY; TUBERCULOSIS;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HUMANS; MALE; PSORIASIS; TUBERCULOSIS, SPLENIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70449119151     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962009000400016     Document Type: Article

References (14)

1. Zeichner JA, Lebwohl M. Potential complications associated with the use of biologic agents for psoriasis. Dermatol Clin. 2007;25:207-213 (Pubitemid 46550728)
2. Weinberg JM, Saini R, Tutrone WD. Biological therapy for psoriasis - the first wave: infliximab, etanercept, efalizumab and alefacept. J Drugs Dermatol. 2002;1:303-310
3. Kazlow Stern D, Tripp JM, Ho VC, Lebwohl M. The use of systemic immune moderators in dermatology: an update. Dermatol Clin. 2005;23:259-300. (Pubitemid 40514430)
4. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-850
5. Sampogna F, Sera F, Abeni D, IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Investigators. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol. 2004;122:602-607
6. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005;153:486-497 (Pubitemid 41248202)
7. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol. 2003;49(Suppl2):S112-7.
8. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161:S221-47.
9. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003;48:3013-3022 (Pubitemid 37409310)
10. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148-155 (Pubitemid 36278124)
11. Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59:209-217
12. Guide for primary health care providers: targeted tuberculin testing and treatment of latent tuberculosis infection. [cited 2008 Jan 2]. Available from: www.cdc.gov/tb/pubs/LTBI/pdf/TargetedLTBI05.pdf.
13. Winthrop KL. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor (alpha). Ann Rheum Dis. 2005;64(Suppl4):iv29-30.
14. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52:1766-1772 (Pubitemid 40852885)